# Myostatin (GDF-8) > The body’s brake on muscle growth — a TGF-β-family growth factor whose inhibition is the leading strategy to preserve muscle, including during GLP-1 weight loss. - Also known as: GDF-8, Growth differentiation factor 8, MSTN - Class: Growth Hormone, Metabolic - FDA approved: No - Canonical page: https://www.americanpeptide.com/catalog/myostatin ## Overview Myostatin (GDF-8) is the molecule that limits how much muscle you build. A member of the TGF-β superfamily, it is a negative regulator of skeletal-muscle mass: secreted by muscle itself, it signals muscle to stop growing. That makes myostatin unusual in this catalog — the therapeutic interest is almost entirely in blocking it, not supplying it — and it has become a forward-looking target precisely because the GLP-1 era exposed a problem myostatin inhibition could solve. Myostatin is best understood by what happens when it is missing. Cattle breeds with loss-of-function mutations — the "double-muscled" Belgian Blue — are dramatically more muscular; so are myostatin-null mice, a strain of "bully whippets," and, in a well-documented 2004 case, a human child with a myostatin mutation born unusually strong. The lesson is consistent across species: myostatin is a brake, and releasing it builds muscle. That is why the drug development around it aims to inhibit the pathway — with antibodies, ligand traps, and receptor blockers — rather than administer the growth factor. The clinical targets were originally the diseases of muscle loss: muscular dystrophies, sarcopenia (age-related muscle wasting), and cachexia. Results have been mixed — blocking myostatin reliably adds muscle mass, but translating that into durable strength and function has proven harder — which is the honest state of the field. The forward-looking turn is metabolic. The GLP-1 and dual/triple-agonist drugs produce large weight loss, but a substantial fraction of that loss is lean muscle, not just fat — a growing concern about the *quality* of weight loss as these drugs scale. Myostatin-pathway inhibition is the leading strategy to preserve or build muscle alongside that fat loss, and combinations of incretin agonists with muscle-sparing agents are an active frontier. This is the real "next chapter" beyond first-generation GLP-1 fat loss: not just losing weight, but keeping the muscle. It is also a doping and hype target — "myostatin blockers" are marketed well ahead of the evidence, and the pathway is banned in sport. As a reference entry, myostatin is the target and the science; specific inhibitor drugs are described as research and investigational, not endorsements. ## Mechanism Synthesized as a precursor and processed to a disulfide-linked dimer that signals through the activin type II receptors (ActRIIB) and the Smad2/3 pathway to suppress muscle-fiber growth. Removing or blocking myostatin releases that brake, increasing muscle mass; follistatin is a natural antagonist of this signal. ## Chemistry | Property | Value | | --- | --- | | Molecular weight | 12400 Da | | UniProt | [O14793](https://www.uniprot.org/uniprotkb/O14793) | ## Research areas Studied in: Muscle growth, Body composition, Sarcopenia, Muscular dystrophy, GLP-1 muscle preservation. Guides on this site: - [Longevity & Aging](https://www.americanpeptide.com/research-areas/longevity-aging): Peptides studied across the aging axis — senescence, NAD+, and resilience. - [Growth Hormone & Body Composition](https://www.americanpeptide.com/research-areas/growth-hormone-axis): Secretagogues studied for GH release, IGF-1, and body composition. ## Key research - Negative regulator of muscle — loss of myostatin (cattle, mice, dogs, a human case) produces dramatic muscle overgrowth. - Inhibition as the therapeutic angle — antibodies, ligand traps, and receptor blockers aim to release the brake, not supply the factor. - Muscle-wasting disease — studied in muscular dystrophy, sarcopenia, and cachexia; mass gains are more reliable than functional gains so far. - GLP-1 muscle preservation — a leading strategy to counter the lean-mass loss that accompanies incretin-driven weight loss (the forward-looking use). - ActRIIB/Smad signaling — myostatin acts through activin receptors; follistatin is its natural antagonist. - Not an approved drug — no myostatin-targeting therapy is broadly approved; agents remain investigational. ## Storage, handling & synthesis **Storage.** As a research protein, recombinant myostatin/GDF-8 is handled like other growth factors — stored frozen as lyophilized powder, kept cold and protected from repeated freeze–thaw once reconstituted. **Handling.** A disulfide-linked dimeric protein sensitive to heat, repeated freeze–thaw, and agitation, any of which can disrupt the dimer and reduce activity. **Synthesis.** Myostatin is a processed, disulfide-linked dimer of the TGF-β superfamily — not a solid-phase synthetic peptide. Its mature monomer is ~12.4 kDa and the active form is a ~25 kDa dimer; because it is produced and processed in cells (and is studied as a target rather than supplied as a drug), it has no single small-molecule formula. Most therapeutics in this space are antibodies or engineered receptor traps, which are biologic-grade products in their own right. ## FAQs ### What is myostatin? Myostatin (GDF-8) is a TGF-β-family growth factor that limits skeletal-muscle growth — the body’s brake on muscle mass. Most therapeutic interest is in blocking it to increase muscle, not in administering it. ### Why is myostatin relevant to GLP-1 weight loss? GLP-1 and related drugs cause large weight loss that includes significant muscle, not just fat. Inhibiting the myostatin pathway is the leading approach to preserve muscle during that weight loss — a major forward-looking direction. ### Do myostatin blockers work? Blocking myostatin reliably increases muscle mass in studies, but translating that into lasting strength and function has been inconsistent. No myostatin-targeting drug is broadly approved; they remain investigational. ### Is this medical advice? No — this is a research and educational reference. Myostatin-targeting agents are investigational and, as a pathway, are banned in sport. ## Latest research Recent trials and publications mentioning Myostatin, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily). ### Recent trials - [Long-term Adaptations of Skeletal Muscle After Hybrid Training](https://clinicaltrials.gov/study/NCT07341711) — RECRUITING · NA · NCT07341711 - [A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy](https://clinicaltrials.gov/study/NCT05115110) — ACTIVE_NOT_RECRUITING · PHASE2, PHASE3 · NCT05115110 - [Combined Aerobic and Resistance Exercise in Peritoneal Dialysis Patients](https://clinicaltrials.gov/study/NCT07634211) — COMPLETED · NA · NCT07634211 - [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults](https://clinicaltrials.gov/study/NCT07487376) — RECRUITING · PHASE1 · NCT07487376 - [Muscle Vibration as a Countermeasure Against Hypoactivity-induced](https://clinicaltrials.gov/study/NCT07021079) — RECRUITING · NA · NCT07021079 - [Study of Parameters of Osteosarcopenia in Patients With Hip Fracture](https://clinicaltrials.gov/study/NCT04730622) — RECRUITING · NCT04730622 --- Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/myostatin Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com. Research reference only — computational and educational content, not medical advice.